Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 3NIH 1FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Advanced Malignant Solid Neoplasm 1

Interventions

Cyclophosphamide 2040Radiotherapy 1854Cisplatin 1820Carboplatin 1530Gemcitabine 1432Paclitaxel 1289Bevacizumab 1267Docetaxel 1200pembrolizumab 1196Oxaliplatin 1157Capecitabine 1140Fluorouracil 1059Dexamethasone 971Rituximab 918Nivolumab 908Magnetic Resonance Spectroscopy 858Etoposide 839Doxorubicin 823Drug Therapy 789Radiosurgery 774Irinotecan 774Cytarabine 736fludarabine 714Leucovorin 674Lenalidomide 608fludarabine phosphate 564Temozolomide 552Filgrastim 540Radiation 539Cetuximab 535

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Interventional × PT-100 dipeptide × Clear all
NCT05703542 2025-07-18

BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

Dana-Farber Cancer Institute

Phase 1 Recruiting
24 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04171219 2025-05-16

Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
31 enrolled 15 charts
Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT00489710 2023-08-22

Talabostat in Treating Patients With Metastatic Kidney Cancer

University of Nebraska

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡